Patents by Inventor Richard F. Ambinder

Richard F. Ambinder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMAGING AND THERAPY OF VIRUS-ASSOCIATED TUMORS
    Publication number: 20170202985
    Abstract: The present invention features compositions and methods for detecting, selecting a treatment method for, monitoring, and treating a neoplasia associated with a viral infection.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 20, 2017
    Inventors: Martin G. Pomper, Richard F. Ambinder, Jun O. Liu, Curtis R. Chong, Jianmeng Chen
  • Cyclophosphamide in combination with immune therapeutics
    Patent number: 9539267
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: January 10, 2017
    Assignee: The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Richard F. Ambinder
  • METHODS FOR DETECTION AND DIFFERENTIATION OF ORIGIN OF VIRAL DNA
    Publication number: 20140235484
    Abstract: The invention disclosed herein provides methods for identifying the origin of viral DNA in a sample by detecting the methylation state of at least one CpG site on a target site of the genome of a virus of interest, and determining whether the origin of the viral DNA is from a cell, such as a tumor cell, or a virion, wherein when the methylation state is positive for methylation, the viral DNA is from a cell, and wherein when the methylation state is negative for methylation, the viral DNA is from a virion. Use of these methods for diagnosis or monitoring, and/or treatment of a subject infected with a virus known to cause cancer and related disease are also provided.
    Type: Application
    Filed: February 18, 2014
    Publication date: August 21, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Richard F. Ambinder, Meir Shamay
  • Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
    Patent number: 8383096
    Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: February 26, 2013
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Richard F. Ambinder, Yiping Yang, Ivan M. Borrello, Hyam I. Levitsky
  • Cyclophosphamide in Combination with Immune Therapeutics
    Publication number: 20120100162
    Abstract: The present invention relates to methods of treating a cancer and in particular, a B-cell derived cancer, using a lymphocytotoxic but hematopoeitic cell sparing high-dose pulsed amount of an oxazaphosphorine drug, either alone, or in combination with immune therapeutics such as, for example, monoclonal antibodies that selectively bind B-cell specific antigens.
    Type: Application
    Filed: September 14, 2011
    Publication date: April 26, 2012
    Applicants: Accentia Biopharmaceuticals, Inc., The Johns Hopkins University
    Inventors: Robert A. Brodsky, Richard J. Jones, Richard F. Ambinder
  • CANCER IMMUNOTHERAPY WITH A VIRAL ANTIGEN-DEFINED, IMMUNOMODULATOR-SECRETING CELL VACCINE
    Publication number: 20100272760
    Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie
    Type: Application
    Filed: April 8, 2010
    Publication date: October 28, 2010
    Applicant: JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Richard F. Ambinder, Yiping Yang, Ivan M. Borrello, Hyam I. Levitsky
  • Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
    Patent number: 7740871
    Abstract: A human cell line, which lacks major histocompatibility class I (MHC-I) antigens and major histocompatibility class II (MHC-II) antigens and which has been modified to comprise and express (i) a nucleotide sequence encoding an immunomodulator and (ii) a nucleotide sequence encoding a viral antigen, and a method of inducing or stimulating an immune response in a human to a viral-associated disease or cancer comprising administering to the human (i) the aforementioned human cell line in an amount sufficient to induce or stimulate an immune response to the viral associated disease or cancer, (ii) a human cell line, which lacks MHC-I and MHC-11 antigens and which has been modified to comprise and express a nucleotide sequence encoding an immunomodulator, and a human cell line, which lacks MHC-I and MHC-II antigens and which has been modified to comprise and express a nucleotide sequence encoding an antigen of EBV, simultaneously or sequentially in either order, by the same or different routes, in amounts sufficie
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: June 22, 2010
    Assignee: Johns Hopkins University School of Medicine
    Inventors: Richard F. Ambinder, Yiping Yang, Ivan M. Borrello, Hyam I. Levitsky